The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...
Heart failure presents a growing public health problem both in Estonia and across Europe. At the same time, ...
Heart failure risk prediction improves when gut-derived biomarkers are added to traditional models, revealing residual risk ...
CHF combined with high SDOH burdens significantly increases all-cause and cardiovascular mortality risks. The study analyzed data from 38,947 participants, focusing on CHF and SDOH impacts on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results